SlideShare a Scribd company logo
1
Dr Philippe Gabant
Co-founder & CSO
pgabant@syngulon.com
Guy Hélin
Co-founder & CEO
ghelin@syngulon.com
Selection Technology Using Bacteriocin-Immunity
to Improve Microbial Fermentation
Agenda
1. Synthetic biology
2. Heterogeneity
3. Key issues in the control of microorganisms
4. Regulatory guidance about antibiotics use in bioproduction
5. Bacteriocins: What are they? Why use them?
6. A bacteriocin-based fermentation peer police
7. Syngulon Technology self-supporting = with bacteriocins secretion
8. Syngulon Technology with immunity only
9. Comparisons of overexpression
10. Control of contamination and genetic drift: test bench
11. pDNA production with Syngulon technology
12. Syngulon TEAM / SAB / R&D Partners
13. Q&A 2
“Blank” chassis
Constructed by modules (parts)
Behavior code based
Non self replicative
Possible contamination by external code
“Evolutionary” based chassis
Constructed by modules (parts)
Behavior code based
Self coding and self replicative
Possible contamination by external code
Similarities with IT exists but fundamental differences
3
1. Synthetic Biology
industrialization concept “IT versus genes”
2. Heterogeneity in bioreactors
4
Batch 1
Yield: 75%
Batch 2
Yield: 50%
Batch 3
Yield: 90%
A
GOI
B
Confidential
3. Key issues in the control of Microorganisms
Self replicative
Gene of interest
GOI
Two technological solutions
1. Induce the suicide of the cheater (self-police)
2. The fermentation population induces a peer police in the system
KEY ISSUES
1. Antibiotic-free selection
2. Yield increase
3. Genetic stability
4. Easy to use: 100% plasmid-based
4. Regulatory guidance about antibiotics use in bioproduction
“As stated in the “Points to consider in the Characterization of Cell Lines
Used to Produce Biologicals,” it is recommended that penicillin and
other beta-lactam antibiotics be avoided during production, due to the
risk of serious hypersensitivity reactions in patients. If antibiotic
selection is used during production, it is preferable not to use selection
markers which confer resistance to antibiotics in significant clinical use,
in order to avoid unnecessary risk of spread of antibiotic resistance
traits to environmental microbes. Also residual antibiotic in the final
product should be quantitated when possible, and potential for allergy
considered”
6
“Concerning environmental impact and
the use of drug resistance traits, consult
the NIH Guidelines for Research Involving
Recombinant DNA Molecules, Section III-
A-1-a (59 FR 34496, amended 61 FR
59732). Non-antibiotic selection systems
can also be used.”
5. Bacteriocins: What are they? Why use them?
- Discovered in 1925 by Belgian scientist: “André Gratia (1893–1950):
Forgotten Pioneer of Research into Antimicrobial Agents”
- Heterogenous group of antimicrobial peptides produced ribosomally
by bacteria
- Used to kill related species to reduce competition for resources and space
- Not toxic
- Small peptides that in many cases do not undergo post-translational
modification to be active = Ideal for gene-based peptide engineering1
- Active against antibiotic-resistant bacteria (VRE, MRSA…)2
- Antimicrobial activity at the nanomolar range scale (more active than
most antibiotics)2
- Naturally produced by probiotic strains
- Nisin (E234) is a bacteriocin widely used in the food industry (GRAS status)
- Availability of broad and narrow spectrum of activity 1Cotter et al., Nat. Rev. Microbiol., 2013
2Mathur et al., Front. Microbiol., 2017
3Oppegård et al., Biochemistry, 2015
Scimat/Science Photo Library
Pediocin PA-1 3
André Gratia
7
6. A bacteriocin based fermentation peer police
7. Syngulon Technology self-supporting
= with bacteriocins secretion
Immunity
Target
Gene of interest
Bacteriocin
Selection technology
developed by Syngulon
(EP3035802B1, US patents
9,333,227 / 10,188,114 /
11,427,800, CN ZL
201480057387.2 / ZL
201910882176.7, IN38926,
BR1120160035330/BR1220210
154171) to control microbes
providing:
1. Bacteriocin selection of
expressing clones
2. Yield increase
3. Control of genetic drift
4. 100% plasmid-based
(available in most E coli
strains)
Plasmid
Bacteriocin gene
Immunity gene
9
8. Syngulon Technology with immunity only
New selection technology
developed by Syngulon
(EP3035802B1, US patents
9,333,227 / 10,188,114 /
11,427,800 and CN ZL
201480057387.2 / ZL
201910882176.7, IN389267,
BR1120160035330/BR12202101
54171 + US Patent 11,932,672)
to control microbes providing:
1. Bacteriocin selection of
expressing clones
2. Yield increase
3. Control of genetic drift
4. 100% plasmid-based
(available in most E
coli strains)
Plasmid
Closed and controlled batch fermentor
Immunity
Target
Gene of interest
Bacteriocin
Immunity gene
10
Protein X in E. coli RV308 at 37°C with KanR (pKan-Plac) and with 2 immunities against
microcins C7 and ColV (pBACT-Plac)
70
55
40
35
25
100
0 15’ 30’ 60’ 120’ 0’ 15’ 30’ 60’ 120’
pKan-Plac-X pBACT6.0-Plac-X
Induction time
X
(~40 kDa)
5 g of total extract were analysed by SDS-PAGE
pKan-Plac-X
pBACT6.0-Plac-X
0.67 0.95 1.12 1.48 2.30
0.50 0.60 0.62 0.74 0.95
T=0 15’ 30’ 60’ 120’
OD600nm at different time of induction
11
9. Syngulon technology: comparisons of overexpression
12
Confidential
BL21 (DE3)
BL21 (DE3) / pAutoColV-X
1 2 3 4 5
0% 10% 30% 50% 100%
BL21 (DE3) / pET28b-X BL21 (DE3)
6 7 8 9
0% 10% 30% 50%
1 2 3 4 5 6 7 8 9
After 1 hour of growth, recombinant protein production
is induced with IPTG for 2 hours followed by bacterial cell
analysis (presence of plasmid) and protein SDS-PAGE
analysis (coomassie + western blot)
M
kDa
70
55
40
35
25
15
100
130
170
1 2 3 4 5 M 6 7 8 9 5
pAutoColV-X pET28b-X
Protein X
(~ 42 kDa)
Protein X
(~ 42 kDa)
Coomassie
SDS-PAGE
Western blot:
anti-X
70
55
40
35
25
15
100
130
170
T = 0
T = 3h
Potential contaminants or cells having lost the
plasmid are killed by the bacteriocin (ColV)
produced by the pAutoColV plasmid
Potential contaminants or cells having lost
the plasmid can take over the bacterial
population harbouring the plasmid
High production of the recombinant protein (X) with the self-supporting plasmid
(pAutoColV) compared to the standard plasmid (pET28b) with antibiotic resistance.
With the self-supporting system, contamination and genetic drift of the bacterial
population are better controlled during the recombinant protein production
10. Control of contamination and genetic drift: test bench
Batch fermentation in 200 L bioreactor
using E. coli BL21 (DE3) production strain containing a
Syngulon’s self-supporting expression plasmid
While producing the protein of interest (in blue) the
production strain also secret bacteriocins (in red) in the
fermentation medium. The population of cells containing
the Syngulon’s patented expression plasmids are therefore
inhibiting the growth of cells that loss the plasmid as well
as sensitive contaminants. Cells that contain the plasmids
also express the bacteriocin’s immunity and are therefore
immune to the bacteriocins
25
15
10
35
40
55
70
100
130
170
Recombinant
protein expression
in E. coli BL21 (DE3)
Inhibition halos due to
bacteriocins present in the
cell culture supernatant
Bacteriocin
Protein of interest
Example of a production in 200 L bioreactor with
Syngulon self-supporting expression plasmids
13
14
Construction of pAAV-ImV vector*
PCR fragment
*Vector without ampicillin resistance gene and with only immunity gene of ColV. The selection is
achieved by the addition of ColV bacteriocin in the medium.
Replace the AmpR gene in the
pAAV-RC2 (AmpR) plasmid by the
immunity gene of ColV
M: Molecular weight (bp)
R: restriction by EcoRV/NsiI (validated: 4,7 – 1,4 kb)
M R
400
200
600
800
1000
1500
2000
2500
3000
10000
4000
6000
Validation by restriction of
the pAAV-ImV vector.
15
11. pDNA production with Syngulon technology
Nat Rev Drug Discov. 2019 May ; 18(5): 358–378
Construction of pAAV-MccV vector*
R1 R2
PCR fragment
ColV (MccV) operon
*Vector without ampicillin resistance gene and without addition of other compounds (i.e. antibiotics) in
the culture medium. The selection is achieved by the expression of the ColV bacteriocin and the
associated immunity protein from the ColV operon
Validation by restriction of
the pAAV-MccV vector
M: Molecular weight (bp)
R1: restriction by EcoRI / SpeI (validated: 4,893 - 3 - 1,535 - 0,667 - 0,218 kb)
R2: restriction by BamHI / PmeI (validated: 6 - 3,5 - 0,8 kb)
M R1
400
200
600
800
1000
1500
2000
2500
3000
10000
8000
4000
6000
R2
5000
16
11. pDNA production with Syngulon technology
Replace the AmpR gene in the
pAAV-RC2 (AmpR) plasmid by
the ColV bacteriocin operon.
Nat Rev Drug Discov. 2019 May ; 18(5): 358–378
17
11. pDNA production with Syngulon technology
Figure 3. Competition experiments. (A) Competition Experiment Without Selection. The upper section is a schematic representation of the competition experiments set
up with cell counts at the time of flask inoculation (Time 0) in CFU/mL ± SD. Flask 1 only contains the ampicillin resistant E. coli STABLE (AAV-RC2) strain (blue);
Flask 2 was inoculated with 99% of the strain STABLE (AAV-RC2) (blue) and the 1% of the plasmid-free strain STABLE (red). The competition was made without
adding ampicillin. The lower section of the panel shows the average pDNA extraction obtained from each culture (pDNA µg/mL of Culture) after 20 hours of growth.
60% of pDNA production drift was observed due to the population evolution resulting from the competition by 1% of empty bacteria. (B) Competition Experiment With
Peer Selection. The upper section of the panel represents the experimental set up with cell counts at the time of flask inoculation (Time 0) in CFU/mL ± SD. Flask 1,
contains only the STABLE (AAV-MccV) strain (green); Flask 2 contains 50% of the strain STABLE (AAV-MccV) (green) and 50% of the plasmid-free STABLE strain
(red). The lower section of the panel shows the average pDNA extraction obtained from each culture (pDNA µg/mL of Culture) after 20 hours of growth. No pDNA
production drift was observed from the competition experiment. Showing that the peer selection based of ColV produced by individual’s bacteria containing the pDNA
(AAV-MccV) was able to outcompete pDNA empty STABLE population during fermentation. The experiments were performed in triplicate with duplicate samples.
From El Bakkoury et al, 2024
Control of contamination and
genetic drift with pAAV-MccV vector
18
11. pDNA production with Syngulon technology
Supercoiled plasmid DNA analysis
All three plasmid preparations successfully achieved 95% of the supercoiled form, being only the remaining 5% OC forms.
These results demonstrate that efficient and high quality pDNA production is possible with stable and antibiotic-free plasmids
like pAAV-MccV and pAAV-ImV
pAAV-RC2 (AmpR) pAAV-MccV pAAV-ImV
Superhelical Density
Percentage of supercoiled DNA
pAAV-RC2 pAAV-MccV pAAV-ImV
pAAV-RC2
pAAV-MccV
pAAV-ImV
R&D Partners
Scientific Advisory Board
Pr Joseph Martial (Chairman), ULg, Liège (BE)
Pr Bruno André, ULB, Brussels (BE)
Adj-Pr Mike Chandler, University of Georgetown (USA)
Pr Pascal Hols, UCL, Louvain-la-Neuve (BE)
Pr Didier Mazel, Institut Pasteur, Paris (FR)
Pr Laurence Van Melderen, ULB, Charleroi (BE)
Pr Ruddy Wattiez, UMons, Mons (BE)
IN MEMORIAM
Dr Régis Sodoyer, ex-Sanofi Pasteur, Lyon (FR)
Collaboration with:
Universidad Complutense Madrid (UCM)
Juan Borrero, PhD – Senior Scientist
Team / SAB / R&D Partners
Team
Guy Hélin, Co-founder, CEO
Philippe Gabant, PhD - Co-Founder, CSO
Mohamed El Bakkoury, PhD - CTO Yeast
Luz Perez, PhD - R&D Project Manager
Félix Jaumaux, PhD - R&D Project Manager
Loïc Mues, Ir - R&D Scientist
Kenny Petit, PhD - R&D project manager
Denis Dereinne, PhD student - R&D Scientist
Alex Quintero, PhD - R&D Project Manager
19
13. Q & A
20
Selection Technology Using Bacteriocin-Immunity
to Improve Microbial Fermentation
Dr Philippe Gabant
Co-founder & CSO
pgabant@syngulon.com
Guy Hélin
Co-founder & CEO
ghelin@syngulon.com
Scientific background
Genetic selection (definition)
• A selection is an approach allowing only a sub-population of interest to survive
• The result is an enrichment of only individuals presenting the behavior of interest
(i.e. production of a certain compound)
Development of selections
1. In the 1990 selection for bacteria (clones) having recombinant plasmids (ULB patents):
R&D kits, exclusive license Invitrogen
2. In the 2000 selection for biopharma expression system without antibiotics (ULB
patents): licensing via Delphi Genetics (today part of Catalent)
3. From 2013, NEW selection technology for recombinants products or plasmidic DNA
(Syngulon patents - Dr. Gabant, inventor)
21

More Related Content

Similar to Syngulon - Selection technology May 2024.pdf

Detection of Biofilm
Detection of BiofilmDetection of Biofilm
Ribeiro2015
Ribeiro2015Ribeiro2015
Ribeiro2015
Ana Rafaela Silva
 
Isolation and characterization of an extracellular antifungal protein from an...
Isolation and characterization of an extracellular antifungal protein from an...Isolation and characterization of an extracellular antifungal protein from an...
Isolation and characterization of an extracellular antifungal protein from an...
Maulik Kamdar
 
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
QIAGEN
 
PDC Libraries
PDC LibrariesPDC Libraries
PDC Libraries
Michael Weiner
 
Mammalian & Bacterial Expression
Mammalian & Bacterial ExpressionMammalian & Bacterial Expression
Mammalian & Bacterial Expression
Jesús C. Morales
 
Rloia Pickettiir
Rloia PickettiirRloia Pickettiir
Rloia Pickettiir
Christy Davis
 
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
SSR Institute of International Journal of Life Sciences
 
ijep-03-22531-1
ijep-03-22531-1ijep-03-22531-1
ijep-03-22531-1
KOBRA SALIMIYAN rizi
 
Detection of gm crops
Detection of gm cropsDetection of gm crops
Detection of gm crops
janhavimaurya
 
Strain improvement technique (exam point of view)
Strain improvement technique (exam point of view)Strain improvement technique (exam point of view)
Strain improvement technique (exam point of view)
Sijo A
 
Startvac mechanism of action
Startvac mechanism of action Startvac mechanism of action
Startvac mechanism of action
gilmarti
 
Hybridoma technology
Hybridoma technologyHybridoma technology
Hybridoma technology
NehaSingla51
 
VIGS in barley seedlings leaves
VIGS in barley seedlings leavesVIGS in barley seedlings leaves
VIGS in barley seedlings leaves
lokanadha
 
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
Irta
 
Automation in microbiology, changing concept and defeating challenges
Automation in microbiology, changing concept and defeating challengesAutomation in microbiology, changing concept and defeating challenges
Automation in microbiology, changing concept and defeating challenges
Ayman Allam
 
Biotechnological pharmaceuticals
Biotechnological pharmaceuticalsBiotechnological pharmaceuticals
Biotechnological pharmaceuticals
Gaurav Kr
 
Tilling @ sid
Tilling @ sidTilling @ sid
Tilling @ sid
sidjena70
 
Characterization of Multidrug
Characterization of MultidrugCharacterization of Multidrug
Characterization of Multidrug
د.حسين عليوي الدهموشي
 
GM Food Allergy Biomarkers
GM Food Allergy BiomarkersGM Food Allergy Biomarkers
GM Food Allergy Biomarkers
Mainul Husain
 

Similar to Syngulon - Selection technology May 2024.pdf (20)

Detection of Biofilm
Detection of BiofilmDetection of Biofilm
Detection of Biofilm
 
Ribeiro2015
Ribeiro2015Ribeiro2015
Ribeiro2015
 
Isolation and characterization of an extracellular antifungal protein from an...
Isolation and characterization of an extracellular antifungal protein from an...Isolation and characterization of an extracellular antifungal protein from an...
Isolation and characterization of an extracellular antifungal protein from an...
 
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
Detection and Surveillance of Antibiotic Resistance Genes From Food and Ferti...
 
PDC Libraries
PDC LibrariesPDC Libraries
PDC Libraries
 
Mammalian & Bacterial Expression
Mammalian & Bacterial ExpressionMammalian & Bacterial Expression
Mammalian & Bacterial Expression
 
Rloia Pickettiir
Rloia PickettiirRloia Pickettiir
Rloia Pickettiir
 
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
Cloning_Expression_Outer_Membrane_Protein_Omp38_Aeromonas_hydrophila_Escheric...
 
ijep-03-22531-1
ijep-03-22531-1ijep-03-22531-1
ijep-03-22531-1
 
Detection of gm crops
Detection of gm cropsDetection of gm crops
Detection of gm crops
 
Strain improvement technique (exam point of view)
Strain improvement technique (exam point of view)Strain improvement technique (exam point of view)
Strain improvement technique (exam point of view)
 
Startvac mechanism of action
Startvac mechanism of action Startvac mechanism of action
Startvac mechanism of action
 
Hybridoma technology
Hybridoma technologyHybridoma technology
Hybridoma technology
 
VIGS in barley seedlings leaves
VIGS in barley seedlings leavesVIGS in barley seedlings leaves
VIGS in barley seedlings leaves
 
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
Sponsor Day on animal feeding: Studies of feed additives in experimental cond...
 
Automation in microbiology, changing concept and defeating challenges
Automation in microbiology, changing concept and defeating challengesAutomation in microbiology, changing concept and defeating challenges
Automation in microbiology, changing concept and defeating challenges
 
Biotechnological pharmaceuticals
Biotechnological pharmaceuticalsBiotechnological pharmaceuticals
Biotechnological pharmaceuticals
 
Tilling @ sid
Tilling @ sidTilling @ sid
Tilling @ sid
 
Characterization of Multidrug
Characterization of MultidrugCharacterization of Multidrug
Characterization of Multidrug
 
GM Food Allergy Biomarkers
GM Food Allergy BiomarkersGM Food Allergy Biomarkers
GM Food Allergy Biomarkers
 

Recently uploaded

Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
SOFTTECHHUB
 
Presentation of the OECD Artificial Intelligence Review of Germany
Presentation of the OECD Artificial Intelligence Review of GermanyPresentation of the OECD Artificial Intelligence Review of Germany
Presentation of the OECD Artificial Intelligence Review of Germany
innovationoecd
 
TrustArc Webinar - 2024 Global Privacy Survey
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc Webinar - 2024 Global Privacy Survey
TrustArc Webinar - 2024 Global Privacy Survey
TrustArc
 
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
名前 です男
 
Pushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 daysPushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 days
Adtran
 
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Speck&Tech
 
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with SlackLet's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
shyamraj55
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
SOFTTECHHUB
 
Communications Mining Series - Zero to Hero - Session 1
Communications Mining Series - Zero to Hero - Session 1Communications Mining Series - Zero to Hero - Session 1
Communications Mining Series - Zero to Hero - Session 1
DianaGray10
 
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Driving Business Innovation: Latest Generative AI Advancements & Success StoryDriving Business Innovation: Latest Generative AI Advancements & Success Story
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Safe Software
 
GenAI Pilot Implementation in the organizations
GenAI Pilot Implementation in the organizationsGenAI Pilot Implementation in the organizations
GenAI Pilot Implementation in the organizations
kumardaparthi1024
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
Neo4j
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
Matthew Sinclair
 
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
Edge AI and Vision Alliance
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Paige Cruz
 
Video Streaming: Then, Now, and in the Future
Video Streaming: Then, Now, and in the FutureVideo Streaming: Then, Now, and in the Future
Video Streaming: Then, Now, and in the Future
Alpen-Adria-Universität
 
Essentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FMEEssentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FME
Safe Software
 
Mariano G Tinti - Decoding SpaceX
Mariano G Tinti - Decoding SpaceXMariano G Tinti - Decoding SpaceX
Mariano G Tinti - Decoding SpaceX
Mariano Tinti
 
Building Production Ready Search Pipelines with Spark and Milvus
Building Production Ready Search Pipelines with Spark and MilvusBuilding Production Ready Search Pipelines with Spark and Milvus
Building Production Ready Search Pipelines with Spark and Milvus
Zilliz
 
Serial Arm Control in Real Time Presentation
Serial Arm Control in Real Time PresentationSerial Arm Control in Real Time Presentation
Serial Arm Control in Real Time Presentation
tolgahangng
 

Recently uploaded (20)

Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
Goodbye Windows 11: Make Way for Nitrux Linux 3.5.0!
 
Presentation of the OECD Artificial Intelligence Review of Germany
Presentation of the OECD Artificial Intelligence Review of GermanyPresentation of the OECD Artificial Intelligence Review of Germany
Presentation of the OECD Artificial Intelligence Review of Germany
 
TrustArc Webinar - 2024 Global Privacy Survey
TrustArc Webinar - 2024 Global Privacy SurveyTrustArc Webinar - 2024 Global Privacy Survey
TrustArc Webinar - 2024 Global Privacy Survey
 
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
みなさんこんにちはこれ何文字まで入るの?40文字以下不可とか本当に意味わからないけどこれ限界文字数書いてないからマジでやばい文字数いけるんじゃないの?えこ...
 
Pushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 daysPushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 days
 
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
Cosa hanno in comune un mattoncino Lego e la backdoor XZ?
 
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with SlackLet's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
Let's Integrate MuleSoft RPA, COMPOSER, APM with AWS IDP along with Slack
 
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...
 
Communications Mining Series - Zero to Hero - Session 1
Communications Mining Series - Zero to Hero - Session 1Communications Mining Series - Zero to Hero - Session 1
Communications Mining Series - Zero to Hero - Session 1
 
Driving Business Innovation: Latest Generative AI Advancements & Success Story
Driving Business Innovation: Latest Generative AI Advancements & Success StoryDriving Business Innovation: Latest Generative AI Advancements & Success Story
Driving Business Innovation: Latest Generative AI Advancements & Success Story
 
GenAI Pilot Implementation in the organizations
GenAI Pilot Implementation in the organizationsGenAI Pilot Implementation in the organizations
GenAI Pilot Implementation in the organizations
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
 
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
“Building and Scaling AI Applications with the Nx AI Manager,” a Presentation...
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
 
Video Streaming: Then, Now, and in the Future
Video Streaming: Then, Now, and in the FutureVideo Streaming: Then, Now, and in the Future
Video Streaming: Then, Now, and in the Future
 
Essentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FMEEssentials of Automations: The Art of Triggers and Actions in FME
Essentials of Automations: The Art of Triggers and Actions in FME
 
Mariano G Tinti - Decoding SpaceX
Mariano G Tinti - Decoding SpaceXMariano G Tinti - Decoding SpaceX
Mariano G Tinti - Decoding SpaceX
 
Building Production Ready Search Pipelines with Spark and Milvus
Building Production Ready Search Pipelines with Spark and MilvusBuilding Production Ready Search Pipelines with Spark and Milvus
Building Production Ready Search Pipelines with Spark and Milvus
 
Serial Arm Control in Real Time Presentation
Serial Arm Control in Real Time PresentationSerial Arm Control in Real Time Presentation
Serial Arm Control in Real Time Presentation
 

Syngulon - Selection technology May 2024.pdf

  • 1. 1 Dr Philippe Gabant Co-founder & CSO pgabant@syngulon.com Guy Hélin Co-founder & CEO ghelin@syngulon.com Selection Technology Using Bacteriocin-Immunity to Improve Microbial Fermentation
  • 2. Agenda 1. Synthetic biology 2. Heterogeneity 3. Key issues in the control of microorganisms 4. Regulatory guidance about antibiotics use in bioproduction 5. Bacteriocins: What are they? Why use them? 6. A bacteriocin-based fermentation peer police 7. Syngulon Technology self-supporting = with bacteriocins secretion 8. Syngulon Technology with immunity only 9. Comparisons of overexpression 10. Control of contamination and genetic drift: test bench 11. pDNA production with Syngulon technology 12. Syngulon TEAM / SAB / R&D Partners 13. Q&A 2
  • 3. “Blank” chassis Constructed by modules (parts) Behavior code based Non self replicative Possible contamination by external code “Evolutionary” based chassis Constructed by modules (parts) Behavior code based Self coding and self replicative Possible contamination by external code Similarities with IT exists but fundamental differences 3 1. Synthetic Biology industrialization concept “IT versus genes”
  • 4. 2. Heterogeneity in bioreactors 4 Batch 1 Yield: 75% Batch 2 Yield: 50% Batch 3 Yield: 90% A GOI B Confidential
  • 5. 3. Key issues in the control of Microorganisms Self replicative Gene of interest GOI Two technological solutions 1. Induce the suicide of the cheater (self-police) 2. The fermentation population induces a peer police in the system KEY ISSUES 1. Antibiotic-free selection 2. Yield increase 3. Genetic stability 4. Easy to use: 100% plasmid-based
  • 6. 4. Regulatory guidance about antibiotics use in bioproduction “As stated in the “Points to consider in the Characterization of Cell Lines Used to Produce Biologicals,” it is recommended that penicillin and other beta-lactam antibiotics be avoided during production, due to the risk of serious hypersensitivity reactions in patients. If antibiotic selection is used during production, it is preferable not to use selection markers which confer resistance to antibiotics in significant clinical use, in order to avoid unnecessary risk of spread of antibiotic resistance traits to environmental microbes. Also residual antibiotic in the final product should be quantitated when possible, and potential for allergy considered” 6 “Concerning environmental impact and the use of drug resistance traits, consult the NIH Guidelines for Research Involving Recombinant DNA Molecules, Section III- A-1-a (59 FR 34496, amended 61 FR 59732). Non-antibiotic selection systems can also be used.”
  • 7. 5. Bacteriocins: What are they? Why use them? - Discovered in 1925 by Belgian scientist: “André Gratia (1893–1950): Forgotten Pioneer of Research into Antimicrobial Agents” - Heterogenous group of antimicrobial peptides produced ribosomally by bacteria - Used to kill related species to reduce competition for resources and space - Not toxic - Small peptides that in many cases do not undergo post-translational modification to be active = Ideal for gene-based peptide engineering1 - Active against antibiotic-resistant bacteria (VRE, MRSA…)2 - Antimicrobial activity at the nanomolar range scale (more active than most antibiotics)2 - Naturally produced by probiotic strains - Nisin (E234) is a bacteriocin widely used in the food industry (GRAS status) - Availability of broad and narrow spectrum of activity 1Cotter et al., Nat. Rev. Microbiol., 2013 2Mathur et al., Front. Microbiol., 2017 3Oppegård et al., Biochemistry, 2015 Scimat/Science Photo Library Pediocin PA-1 3 André Gratia 7
  • 8. 6. A bacteriocin based fermentation peer police
  • 9. 7. Syngulon Technology self-supporting = with bacteriocins secretion Immunity Target Gene of interest Bacteriocin Selection technology developed by Syngulon (EP3035802B1, US patents 9,333,227 / 10,188,114 / 11,427,800, CN ZL 201480057387.2 / ZL 201910882176.7, IN38926, BR1120160035330/BR1220210 154171) to control microbes providing: 1. Bacteriocin selection of expressing clones 2. Yield increase 3. Control of genetic drift 4. 100% plasmid-based (available in most E coli strains) Plasmid Bacteriocin gene Immunity gene 9
  • 10. 8. Syngulon Technology with immunity only New selection technology developed by Syngulon (EP3035802B1, US patents 9,333,227 / 10,188,114 / 11,427,800 and CN ZL 201480057387.2 / ZL 201910882176.7, IN389267, BR1120160035330/BR12202101 54171 + US Patent 11,932,672) to control microbes providing: 1. Bacteriocin selection of expressing clones 2. Yield increase 3. Control of genetic drift 4. 100% plasmid-based (available in most E coli strains) Plasmid Closed and controlled batch fermentor Immunity Target Gene of interest Bacteriocin Immunity gene 10
  • 11. Protein X in E. coli RV308 at 37°C with KanR (pKan-Plac) and with 2 immunities against microcins C7 and ColV (pBACT-Plac) 70 55 40 35 25 100 0 15’ 30’ 60’ 120’ 0’ 15’ 30’ 60’ 120’ pKan-Plac-X pBACT6.0-Plac-X Induction time X (~40 kDa) 5 g of total extract were analysed by SDS-PAGE pKan-Plac-X pBACT6.0-Plac-X 0.67 0.95 1.12 1.48 2.30 0.50 0.60 0.62 0.74 0.95 T=0 15’ 30’ 60’ 120’ OD600nm at different time of induction 11 9. Syngulon technology: comparisons of overexpression
  • 12. 12 Confidential BL21 (DE3) BL21 (DE3) / pAutoColV-X 1 2 3 4 5 0% 10% 30% 50% 100% BL21 (DE3) / pET28b-X BL21 (DE3) 6 7 8 9 0% 10% 30% 50% 1 2 3 4 5 6 7 8 9 After 1 hour of growth, recombinant protein production is induced with IPTG for 2 hours followed by bacterial cell analysis (presence of plasmid) and protein SDS-PAGE analysis (coomassie + western blot) M kDa 70 55 40 35 25 15 100 130 170 1 2 3 4 5 M 6 7 8 9 5 pAutoColV-X pET28b-X Protein X (~ 42 kDa) Protein X (~ 42 kDa) Coomassie SDS-PAGE Western blot: anti-X 70 55 40 35 25 15 100 130 170 T = 0 T = 3h Potential contaminants or cells having lost the plasmid are killed by the bacteriocin (ColV) produced by the pAutoColV plasmid Potential contaminants or cells having lost the plasmid can take over the bacterial population harbouring the plasmid High production of the recombinant protein (X) with the self-supporting plasmid (pAutoColV) compared to the standard plasmid (pET28b) with antibiotic resistance. With the self-supporting system, contamination and genetic drift of the bacterial population are better controlled during the recombinant protein production 10. Control of contamination and genetic drift: test bench
  • 13. Batch fermentation in 200 L bioreactor using E. coli BL21 (DE3) production strain containing a Syngulon’s self-supporting expression plasmid While producing the protein of interest (in blue) the production strain also secret bacteriocins (in red) in the fermentation medium. The population of cells containing the Syngulon’s patented expression plasmids are therefore inhibiting the growth of cells that loss the plasmid as well as sensitive contaminants. Cells that contain the plasmids also express the bacteriocin’s immunity and are therefore immune to the bacteriocins 25 15 10 35 40 55 70 100 130 170 Recombinant protein expression in E. coli BL21 (DE3) Inhibition halos due to bacteriocins present in the cell culture supernatant Bacteriocin Protein of interest Example of a production in 200 L bioreactor with Syngulon self-supporting expression plasmids 13
  • 14. 14
  • 15. Construction of pAAV-ImV vector* PCR fragment *Vector without ampicillin resistance gene and with only immunity gene of ColV. The selection is achieved by the addition of ColV bacteriocin in the medium. Replace the AmpR gene in the pAAV-RC2 (AmpR) plasmid by the immunity gene of ColV M: Molecular weight (bp) R: restriction by EcoRV/NsiI (validated: 4,7 – 1,4 kb) M R 400 200 600 800 1000 1500 2000 2500 3000 10000 4000 6000 Validation by restriction of the pAAV-ImV vector. 15 11. pDNA production with Syngulon technology Nat Rev Drug Discov. 2019 May ; 18(5): 358–378
  • 16. Construction of pAAV-MccV vector* R1 R2 PCR fragment ColV (MccV) operon *Vector without ampicillin resistance gene and without addition of other compounds (i.e. antibiotics) in the culture medium. The selection is achieved by the expression of the ColV bacteriocin and the associated immunity protein from the ColV operon Validation by restriction of the pAAV-MccV vector M: Molecular weight (bp) R1: restriction by EcoRI / SpeI (validated: 4,893 - 3 - 1,535 - 0,667 - 0,218 kb) R2: restriction by BamHI / PmeI (validated: 6 - 3,5 - 0,8 kb) M R1 400 200 600 800 1000 1500 2000 2500 3000 10000 8000 4000 6000 R2 5000 16 11. pDNA production with Syngulon technology Replace the AmpR gene in the pAAV-RC2 (AmpR) plasmid by the ColV bacteriocin operon. Nat Rev Drug Discov. 2019 May ; 18(5): 358–378
  • 17. 17 11. pDNA production with Syngulon technology Figure 3. Competition experiments. (A) Competition Experiment Without Selection. The upper section is a schematic representation of the competition experiments set up with cell counts at the time of flask inoculation (Time 0) in CFU/mL ± SD. Flask 1 only contains the ampicillin resistant E. coli STABLE (AAV-RC2) strain (blue); Flask 2 was inoculated with 99% of the strain STABLE (AAV-RC2) (blue) and the 1% of the plasmid-free strain STABLE (red). The competition was made without adding ampicillin. The lower section of the panel shows the average pDNA extraction obtained from each culture (pDNA µg/mL of Culture) after 20 hours of growth. 60% of pDNA production drift was observed due to the population evolution resulting from the competition by 1% of empty bacteria. (B) Competition Experiment With Peer Selection. The upper section of the panel represents the experimental set up with cell counts at the time of flask inoculation (Time 0) in CFU/mL ± SD. Flask 1, contains only the STABLE (AAV-MccV) strain (green); Flask 2 contains 50% of the strain STABLE (AAV-MccV) (green) and 50% of the plasmid-free STABLE strain (red). The lower section of the panel shows the average pDNA extraction obtained from each culture (pDNA µg/mL of Culture) after 20 hours of growth. No pDNA production drift was observed from the competition experiment. Showing that the peer selection based of ColV produced by individual’s bacteria containing the pDNA (AAV-MccV) was able to outcompete pDNA empty STABLE population during fermentation. The experiments were performed in triplicate with duplicate samples. From El Bakkoury et al, 2024 Control of contamination and genetic drift with pAAV-MccV vector
  • 18. 18 11. pDNA production with Syngulon technology Supercoiled plasmid DNA analysis All three plasmid preparations successfully achieved 95% of the supercoiled form, being only the remaining 5% OC forms. These results demonstrate that efficient and high quality pDNA production is possible with stable and antibiotic-free plasmids like pAAV-MccV and pAAV-ImV pAAV-RC2 (AmpR) pAAV-MccV pAAV-ImV Superhelical Density Percentage of supercoiled DNA pAAV-RC2 pAAV-MccV pAAV-ImV pAAV-RC2 pAAV-MccV pAAV-ImV
  • 19. R&D Partners Scientific Advisory Board Pr Joseph Martial (Chairman), ULg, Liège (BE) Pr Bruno André, ULB, Brussels (BE) Adj-Pr Mike Chandler, University of Georgetown (USA) Pr Pascal Hols, UCL, Louvain-la-Neuve (BE) Pr Didier Mazel, Institut Pasteur, Paris (FR) Pr Laurence Van Melderen, ULB, Charleroi (BE) Pr Ruddy Wattiez, UMons, Mons (BE) IN MEMORIAM Dr Régis Sodoyer, ex-Sanofi Pasteur, Lyon (FR) Collaboration with: Universidad Complutense Madrid (UCM) Juan Borrero, PhD – Senior Scientist Team / SAB / R&D Partners Team Guy Hélin, Co-founder, CEO Philippe Gabant, PhD - Co-Founder, CSO Mohamed El Bakkoury, PhD - CTO Yeast Luz Perez, PhD - R&D Project Manager Félix Jaumaux, PhD - R&D Project Manager Loïc Mues, Ir - R&D Scientist Kenny Petit, PhD - R&D project manager Denis Dereinne, PhD student - R&D Scientist Alex Quintero, PhD - R&D Project Manager 19
  • 20. 13. Q & A 20 Selection Technology Using Bacteriocin-Immunity to Improve Microbial Fermentation Dr Philippe Gabant Co-founder & CSO pgabant@syngulon.com Guy Hélin Co-founder & CEO ghelin@syngulon.com
  • 21. Scientific background Genetic selection (definition) • A selection is an approach allowing only a sub-population of interest to survive • The result is an enrichment of only individuals presenting the behavior of interest (i.e. production of a certain compound) Development of selections 1. In the 1990 selection for bacteria (clones) having recombinant plasmids (ULB patents): R&D kits, exclusive license Invitrogen 2. In the 2000 selection for biopharma expression system without antibiotics (ULB patents): licensing via Delphi Genetics (today part of Catalent) 3. From 2013, NEW selection technology for recombinants products or plasmidic DNA (Syngulon patents - Dr. Gabant, inventor) 21